← Back to Search

Other

Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases

N/A
Waitlist Available
Research Sponsored by Precision Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

The purpose of this study is to improve upon and validate the prognostic and/or predictive accuracy of a drug response marker by the development of improved alternative algorithms based on the actual clinical outcome of retrospective cases.

Eligible Conditions
  • Ovarian Cancer
  • Peritoneal Neoplasm

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Ovarian, Peritoneal, Fallopian CancerExperimental Treatment1 Intervention
Recurrent, Peristent or Refractory

Find a Location

Who is running the clinical trial?

Precision TherapeuticsLead Sponsor
6 Previous Clinical Trials
3,839 Total Patients Enrolled
Holly Gallion, MDStudy DirectorVice President, Clinical Affairs
1 Previous Clinical Trials
76 Total Patients Enrolled
~31 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top